A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

Recruiting

Phase 2

AP306A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

Sponsor:

R1 Therapeutics

Code:

NCT06712654

Conditions

Hyperphosphatemia

Chronic Kidney Disease Requiring Chronic Dialysis

End Stage Renal Disease on Dialysis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AP306 75 mg BID

AP306 125 mg BID

AP306 150 mg BID

AP306 75 mg TID

AP306 100 mg TID

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-19. This information was provided to ClinicalTrials.gov by R1 Therapeutics on 2026-06-09.